The MUSC Hollings Cancer Center recieved a grant designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers. 

The grant includes three projects including phase II clinical trial of a new therapy for the treatment of advanced hepatocellular carcinoma (HCC), the most common primrary malignant cancer of the liver and one that experiences one of the highest mortality rates among cancers.

 

More at MUSC News